Upstream Bio Announces Positive Phase 2 Results

By Greg Peters • Tuesday, September 02 15:38 • Permanent Link

Upstream Bio, Inc. (NASDAQ: UPB) has just announced positive top-line results from the phase 2 vibrant trial evaluating Verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The 24-week study showed significant and clinically meaningful reductions in the endoscopic nasal polyp score (NPS) and nasal congestion score (NCS) in participants who received Verekitug.

In the vibrant trial, Verekitug dosed at 100mg every 12 weeks led to a statistically significant and clinically meaningful reduction from baseline in the placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001). Additionally, a significant reduction in the need for surgery or systemic corticosteroids was observed, with no serious adverse events reported. The trial also demonstrated a reduction in the nasal congestion score (NCS) by -0.8 (p=0.0003).

The company highlighted that these results suggest Verekitug's potential to advance the standard of care in the treatment of CRSwNP. Management expressed confidence in Verekitug's unique profile and its potential to be an important addition to existing biologic options for the treatment of CRSwNP.

Moreover, the trial results could offer insight into Verekitug’s potential clinical utility in other respiratory diseases, including severe asthma. This is particularly significant as over 40% of people with severe asthma also have CRSwNP, demonstrating a strong association between the two conditions.

Dr. Aaron Deykin, Chief Medical Officer and Head of Research & Development at Upstream Bio, emphasized the trial results as an important milestone in the development of Verekitug, reinforcing earlier observations that Verekitug’s high potency has the potential to translate into clinical attributes distinct from those offered by any currently available therapy.

The company plans to present further details from the vibrant trial at an upcoming medical conference and engage with global regulatory authorities on the continued development of Verekitug.

Today the company's shares have moved 7.46% to a price of $18.4085. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.